Lindberg Pia, Billström Anita, Kinnby Bertil
School of Dentistry, Odontological Faculty, Malmö University College, S-205 06 Malmö, Sweden.
Inflammopharmacology. 2003;11(3):267-76. doi: 10.1163/156856003322315613.
Roquinimex is a drug with effects on inflammation and tumors. The pharmacological effect is not fully understood, and the molecular mechanism most characterized in vitro is an increase of plasminogen activator inhibitor type 2 (PAI-2) in human peripheral blood monocytes. The aims were to investigate peripheral pharmacological effects of roquinimex on peripheral blood monocytes and dog gingival fluid (GCF).
Six dogs were used in a cross-over study. The amount of GCF was determined with a Periotron. The PAI-2 concentration in GCF was determined with ELISA. Monocytes were isolated from peripheral blood.
Dogs treated with the drug had significantly lower GCF flow values and the PAI-2 concentration in GCF was higher, but no effect was seen on peripheral monocytes.
Roquinimex treatment led to a consistently decreased flow rate of GCF and a higher local concentration of PAI-2 in GCF.
罗喹美克是一种对炎症和肿瘤有作用的药物。其药理作用尚未完全明确,体外最具特征的分子机制是人类外周血单核细胞中纤溶酶原激活物抑制剂2(PAI - 2)增加。目的是研究罗喹美克对外周血单核细胞和犬龈沟液(GCF)的外周药理作用。
在一项交叉研究中使用了6只犬。用牙周测量仪测定GCF量。用酶联免疫吸附测定法测定GCF中PAI - 2浓度。从外周血中分离单核细胞。
接受该药物治疗的犬GCF流量值显著降低,GCF中PAI - 2浓度较高,但对外周单核细胞未见影响。
罗喹美克治疗导致GCF流速持续降低以及GCF中PAI - 2局部浓度升高。